Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBPP) Assets Average (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Assets Average for 12 consecutive years, with $255852.0 as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 45.16% to $255852.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $255852.0, a 45.16% increase, with the full-year FY2025 number at $217856.0, down 15.35% from a year prior.
  • Assets Average was $255852.0 for Q4 2025 at Regen BioPharma, up from $235734.5 in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.3 million in Q3 2021 to a low of $150149.0 in Q1 2024.
  • A 5-year average of $427793.4 and a median of $287989.5 in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 1109.96% in 2021, then plummeted 63.41% in 2024.
  • Regen BioPharma's Assets Average stood at $973670.0 in 2021, then tumbled by 50.03% to $486555.0 in 2022, then plummeted by 47.27% to $256572.5 in 2023, then plummeted by 31.31% to $176250.0 in 2024, then skyrocketed by 45.16% to $255852.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Assets Average are $255852.0 (Q4 2025), $235734.5 (Q3 2025), and $183161.5 (Q2 2025).